Zynerba Pharmaceuticals Inc. Also see "AllTranz Inc." - Scrip, 1 March, 2010. has technology suitable for making pro-drugs out of opioids and cannabinoids, and it thinks these can be developed as treatments for a wide range of indications, from neuropathic pain to addiction, pancreatitis, and more. The company is leading, however, with a gel formulation that combines cannabidiol and penetration enhancers to treat the pain of osteoarthritis as well as strains and sprains.
[Ocelus Ltd.] Also see "Ocelus Ltd." - Scrip, 1 March, 2010. hopes to extend transdermal delivery to macromolecules. Its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?